- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06308393
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
March 6, 2024 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Pharmacokinetic Profile of RSS0393 Ointment as a Single and Multiple Dose Ascending Local Dermal Administration in Healthy and Adult Subjects With Psoriasis
Randomized, double-blind, placebo-controlled study of RSS0393 ointment in healthy and psoriatic subjects
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
88
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shuang Li
- Phone Number: 18604031725
- Email: Shuang.li.sl100@hengrui.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy Volunteers:
- Sign informed consent before the test, fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the requirements of the test plan
- The age of signing the informed consent must be ≥18 years old and ≤55 years old, male or female
- Male subjects weighed ≥50 kg, female subjects weighed ≥45 kg, and body mass index (BMI) was in the range of 19.0~26.0 kg/m2
Patients :
- The age of signing the informed consent must be ≥18 years old and ≤55 years old, male or female;
- Male subject ≥50 kg, female subject ≥45 kg, body mass index (BMI) in the range of 19.0~26.0 kg/m2 (including boundary values)
- At the time of screening and baseline, the clinical diagnosis of psoriasis was at least 6 months
- During screening, the condition of the subjects was in a stable stage, requiring no new skin lesions, no continuous expansion of original skin lesions, and no obvious features of skin inflammation within 6 months before screening
Exclusion Criteria:
- Healthy Volunteers:
- The subject has skin conditions that may affect the evaluation of the administration site
- Patients with severe infection, severe trauma or major surgical operation within 3 months before screening; Patients who plan to undergo surgery during the trial period and within 2 weeks after the end of the trial;
- Suspected allergy to the investigational drug product or any component of the investigational drug product
- Persons who have participated in clinical trials of any drug or medical device within 3 months prior to screening, or who are within 5 half-lives of the drug before screening (if the 5 half-lives exceed 3 months); Participants in clinical trials are defined as those who have given informed consent to clinical trials and have used investigational drugs (including placebo) or investigational medical devices;
- Those who had a history of smoking in the 3 months prior to screening or those who were positive in the screening period;
- Alcoholics within 3 months prior to screening or those who test positive for alcohol breath test during screening;
- Those who have a history of drug abuse, drug dependence or positive drug screening during the screening period;
- Pregnant or lactating women, pregnancy is defined as the female state from pregnancy to termination of pregnancy and the blood β-HCG test is positive during the screening period;
Patients :
- Subjects had skin conditions other than psoriasis that could affect the evaluation of the study drug administration site
- Suspected allergy to the investigational drug product or any component of the investigational drug product;
- Subjects had a history of any active malignancy or malignancy in the 5 years prior to the screening visit, except skin squamous cell carcinoma or basal cell carcinoma, or cervical cancer in situ, which had resolved after treatment
- Pre-existing or current clinically significant cardiovascular, liver, neurological, respiratory, blood, gastrointestinal, immune, and kidney diseases or a history of psychiatric disorders that may affect study results or affect drug absorption, distribution, metabolism, and excretion or place subjects at undue risk
- Participants who had a history of depression and/or were clinically deemed to be at risk of suicide during the screening period and at baseline were excluded
- Currently has an active tuberculosis infection, or chest radiography indicates the presence of an active tuberculosis infection
- Those who had undergone any surgery within 1 month prior to screening, or had not recovered as determined by the investigator, or had planned any surgery between the study period and 4 weeks after the study ended
- The white blood cell count, neutrophil count, lymphocyte count, or hemoglobin in the blood routine examination during screening were out of the normal reference range and were deemed unsuitable for participation in this study by the investigators
- Screening hepatitis B surface antigen, hepatitis C antibody, HIV antibody test any of the positive results;
- Individuals who have participated in clinical trials of any drug or medical device within 3 months prior to signing the informed consent or within 5 half-lives of the investigational drug (whichever is older) (except those who have participated in other clinical trials but failed to be screened and administered)
- The subject has any other condition that the investigator or sponsor considers unsuitable for study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group 1
Single dose in healthy subjects
|
RSS0393 ointment;RSS0393 ointment placebo
|
Experimental: Treatment group 2
Multiple dose in healthy subjects
|
RSS0393 ointment;RSS0393 ointment placebo
|
Experimental: Treatment group 3
Multiple dose in patients
|
RSS0393 ointment;RSS0393 ointment placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percent of Local skin tolerance was assessed as moderate or higher(Single dose in healthy subjects)
Time Frame: 0.5, 2, 4, 12 post -dose day 1, day 2, day 3, day 5, and day 8
|
0.5, 2, 4, 12 post -dose day 1, day 2, day 3, day 5, and day 8
|
The percent of Local skin tolerance was assessed as moderate or higher (Multiple dose in healthy subjects)
Time Frame: 0.5, 2, 4, 12 post-dose day 1, 0.5post-dose on day2、day3、day4、day5、day6, 0.5, 2, 4, 12 post-dose day7, day8, day9, day11, day14
|
0.5, 2, 4, 12 post-dose day 1, 0.5post-dose on day2、day3、day4、day5、day6, 0.5, 2, 4, 12 post-dose day7, day8, day9, day11, day14
|
Measurement of blood examination(Multiple dose in patients )
Time Frame: Day 1, day 28, day 42 post-dose
|
Day 1, day 28, day 42 post-dose
|
Measurement of urine examination(Multiple dose in patients )
Time Frame: Day 1, day 28, day 42 post-dose
|
Day 1, day 28, day 42 post-dose
|
Measurement of Blood Chemistry examination(Multiple dose in patients )
Time Frame: Day 1, day 28, day 42 post-dose
|
Day 1, day 28, day 42 post-dose
|
Measurement of coagulation function examination(Multiple dose in patients )
Time Frame: Day 1, day 28, day 42 post-dose
|
Day 1, day 28, day 42 post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC0-t (Single dose in healthy subjects)
Time Frame: pre-dose,1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
pre-dose,1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
AUC0-∞(Single dose in healthy subjects)
Time Frame: pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
Tmax(Single dose in healthy subjects)
Time Frame: pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
Cmax(Single dose in healthy subjects)
Time Frame: pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
t1/2(Single dose in healthy subjects)
Time Frame: pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
CL/F(Single dose in healthy subjects)
Time Frame: pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
Vz/F(Single dose in healthy subjects)
Time Frame: pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
pre-dose, 1, 2 , 4, 8, 12 , 24, 48, 96, 168 post-dose
|
AUC0-t (Multiple dose in healthy subjects)
Time Frame: pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
AUC0-∞(Multiple dose in healthy subjects)
Time Frame: pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
Tmax(Multiple dose in healthy subjects)
Time Frame: pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
Cmax(Multiple dose in healthy subjects)
Time Frame: pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
t1/2(Multiple dose in healthy subjects)
Time Frame: pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
CL/F(Multiple dose in healthy subjects)
Time Frame: pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
Vz/F(Multiple dose in healthy subjects)
Time Frame: pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
pre-dose, 1 ,2 , 4 , 8 , 12 , 24 post-dose Day1; pre-dose Day5 ; pre-dose Day6; pre-dose Day7; 1 , 2 , 4 , 8 , 12 , 24 , 48 , 96 , 168 post-dose Day7
|
Absolute change in PASI score relative to baseline(Multiple dose in patients )
Time Frame: Day 7, Day 14, Day 28 post-dose
|
Day 7, Day 14, Day 28 post-dose
|
The percentage change in PASI score relative to baseline((Multiple dose in patients )
Time Frame: Day 7, Day 14, Day 28 post-dose
|
Day 7, Day 14, Day 28 post-dose
|
The percentage of PASI50、PASI75、PASI90、PASI100(Multiple dose in patients )
Time Frame: Day 7, Day 14, Day 28 post-dose
|
Day 7, Day 14, Day 28 post-dose
|
The percentage of subjects' achieving PGA score of 0 or 1 and which improvement ≥ 2 from baseline (Multiple dose in patients )
Time Frame: Day 7, Day 14, Day 28 post-dose
|
Day 7, Day 14, Day 28 post-dose
|
The percentage of subjects' inPGA score improvement ≥ 2 from baseline(Multiple dose in patients )
Time Frame: Day 7, Day 14, Day 28 post-dose
|
Day 7, Day 14, Day 28 post-dose
|
Absolute change in BSA score relative to baseline(Multiple dose in patients )
Time Frame: Day 7, Day 14, Day 28 post-dose
|
Day 7, Day 14, Day 28 post-dose
|
The percentage change in BSA score relative to baseline(Multiple dose in patients )
Time Frame: Day 7, Day 14, Day 28 post-dose
|
Day 7, Day 14, Day 28 post-dose
|
Pharmacokinetics (PK) : Concentrations of RSS0393(Multiple dose in patients )
Time Frame: Day1 ,Day 7, day 14, Day 28
|
Day1 ,Day 7, day 14, Day 28
|
Pharmacokinetics (PK) : The major metabolites of RSS0393(Multiple dose in patients )
Time Frame: Day1 ,Day 7, day 14, Day 28
|
Day1 ,Day 7, day 14, Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2024
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
February 5, 2024
First Submitted That Met QC Criteria
March 6, 2024
First Posted (Actual)
March 13, 2024
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- RSP61418
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on RSS0393 ointment;Placebo
-
Changchun GeneScience Pharmaceutical Co., Ltd.Recruiting
-
PharmaEssentiaPharmaEssentia Japan K.K.Completed
-
Tufts Medical CenterPfizerWithdrawn
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Reistone Biopharma Company LimitedActive, not recruiting
-
Novartis PharmaceuticalsCompletedHealthy Volunteers | Atopic Dermatitis | Netherton SyndromeNetherlands, United States
-
Creabilis SACompletedAtopic DermatitisUnited Kingdom
-
Hangzhou Yirui Pharmaceutical Technology Co., LtdNot yet recruitingAtopic DermatitisUnited States
-
Topokine Therapeutics, Inc.CompletedLower Eyelid Steatoblepharon (Excess Eyelid Fat)United States
-
Dr. Reddy's Laboratories LimitedCompleted